CN101553470A - 抗菌的喹啉衍生物 - Google Patents

抗菌的喹啉衍生物 Download PDF

Info

Publication number
CN101553470A
CN101553470A CNA2007800449358A CN200780044935A CN101553470A CN 101553470 A CN101553470 A CN 101553470A CN A2007800449358 A CNA2007800449358 A CN A2007800449358A CN 200780044935 A CN200780044935 A CN 200780044935A CN 101553470 A CN101553470 A CN 101553470A
Authority
CN
China
Prior art keywords
alkyl
compound
fit
amino
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800449358A
Other languages
English (en)
Chinese (zh)
Inventor
J·E·G·吉尔蒙特
D·F·A·兰科伊斯
I·多兰奇
K·J·L·M·安德烈斯
A·考尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38126091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101553470(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to CN201510088659.1A priority Critical patent/CN104744361B/zh
Publication of CN101553470A publication Critical patent/CN101553470A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2007800449358A 2006-12-06 2007-12-04 抗菌的喹啉衍生物 Pending CN101553470A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510088659.1A CN104744361B (zh) 2006-12-06 2007-12-04 抗菌的喹啉衍生物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125499 2006-12-06
EP06125499.1 2006-12-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510088659.1A Division CN104744361B (zh) 2006-12-06 2007-12-04 抗菌的喹啉衍生物

Publications (1)

Publication Number Publication Date
CN101553470A true CN101553470A (zh) 2009-10-07

Family

ID=38126091

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510088659.1A Expired - Fee Related CN104744361B (zh) 2006-12-06 2007-12-04 抗菌的喹啉衍生物
CNA2007800449358A Pending CN101553470A (zh) 2006-12-06 2007-12-04 抗菌的喹啉衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510088659.1A Expired - Fee Related CN104744361B (zh) 2006-12-06 2007-12-04 抗菌的喹啉衍生物

Country Status (32)

Country Link
US (1) US8415475B2 (enExample)
EP (1) EP2099758B1 (enExample)
JP (1) JP5466011B2 (enExample)
KR (1) KR101490222B1 (enExample)
CN (2) CN104744361B (enExample)
AP (1) AP2479A (enExample)
AR (1) AR064151A1 (enExample)
AU (1) AU2007328887B2 (enExample)
BR (1) BRPI0720220B8 (enExample)
CA (1) CA2669819C (enExample)
CL (1) CL2007003514A1 (enExample)
CY (1) CY1117766T1 (enExample)
DK (1) DK2099758T3 (enExample)
EA (1) EA016733B1 (enExample)
ES (1) ES2573689T3 (enExample)
HR (1) HRP20160585T1 (enExample)
HU (1) HUE028769T2 (enExample)
IL (1) IL199083A (enExample)
JO (1) JO3271B1 (enExample)
ME (1) ME02498B (enExample)
MX (1) MX2009005978A (enExample)
MY (1) MY181645A (enExample)
NO (1) NO341983B1 (enExample)
NZ (1) NZ576823A (enExample)
PL (1) PL2099758T3 (enExample)
PT (1) PT2099758E (enExample)
RS (1) RS54794B1 (enExample)
SI (1) SI2099758T1 (enExample)
TW (1) TWI406659B (enExample)
UA (1) UA100972C2 (enExample)
WO (1) WO2008068267A1 (enExample)
ZA (1) ZA200903950B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016008381A1 (zh) * 2014-07-14 2016-01-21 辰欣药业股份有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CN105330595A (zh) * 2014-07-14 2016-02-17 南京明德新药研发股份有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CN105601566A (zh) * 2016-02-02 2016-05-25 张敏 一种护理烧伤后感染的药物组合物
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN109069514A (zh) * 2016-03-07 2018-12-21 结核病药物开发全球联盟公司 抗菌化合物及其用途
CN111757879A (zh) * 2018-01-29 2020-10-09 卡地拉健康护理有限公司 用作抗菌剂的杂环化合物
CN114129526A (zh) * 2015-01-27 2022-03-04 詹森药业有限公司 可分散组合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9617244B2 (en) 2012-04-27 2017-04-11 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
PL2841425T3 (pl) 2012-04-27 2016-10-31 Antybakteryjne pochodne chinoliny
ES2628365T3 (es) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
HK1213250A1 (zh) 2012-10-16 2016-06-30 Janssen Pharmaceutica, N.V. RORγT的雜芳基連接的喹啉基調節劑
KR20150070347A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. Ror-감마-t의 메틸렌 결합 퀴놀리닐 조절제
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
AU2014334619A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
CA3198350A1 (en) * 2020-10-22 2022-04-28 Lunella Biotech, Inc. Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018326A1 (en) * 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
DK2301544T3 (da) * 2002-07-25 2013-01-02 Janssen Pharmaceutica Nv Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
ATE444068T1 (de) 2004-01-23 2009-10-15 Janssen Pharmaceutica Nv Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
NZ547277A (en) 2004-01-23 2009-08-28 Janssen Pharmaceutica Nv Substituted quinolines and their use as mycobacterial inhibitors
EA011572B9 (ru) * 2004-01-29 2018-01-31 Янссен Фармацевтика Н.В. Производные хинолина для применения в качестве микобактериальных ингибиторов
ATE390925T1 (de) * 2004-05-28 2008-04-15 Janssen Pharmaceutica Nv Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ME02935B (me) 2004-09-28 2018-04-20 Janssen Pharmaceutica Nv Vezujući domen bakterijske atp sintaze
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016008381A1 (zh) * 2014-07-14 2016-01-21 辰欣药业股份有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CN105330595A (zh) * 2014-07-14 2016-02-17 南京明德新药研发股份有限公司 吡啶衍生物及其作为抗分支杆菌的应用
US9878982B2 (en) 2014-07-14 2018-01-30 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
CN114129526A (zh) * 2015-01-27 2022-03-04 詹森药业有限公司 可分散组合物
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN105601566A (zh) * 2016-02-02 2016-05-25 张敏 一种护理烧伤后感染的药物组合物
CN109069514A (zh) * 2016-03-07 2018-12-21 结核病药物开发全球联盟公司 抗菌化合物及其用途
CN109069514B (zh) * 2016-03-07 2023-12-29 结核病药物开发全球联盟公司 抗菌化合物及其用途
CN111757879A (zh) * 2018-01-29 2020-10-09 卡地拉健康护理有限公司 用作抗菌剂的杂环化合物

Also Published As

Publication number Publication date
CN104744361B (zh) 2021-06-08
CL2007003514A1 (es) 2008-07-11
HK1208437A1 (en) 2016-03-04
ZA200903950B (en) 2010-08-25
MY181645A (en) 2020-12-30
AU2007328887A1 (en) 2008-06-12
CY1117766T1 (el) 2017-05-17
CN104744361A (zh) 2015-07-01
CA2669819C (en) 2016-08-30
US8415475B2 (en) 2013-04-09
BRPI0720220B8 (pt) 2021-05-25
MX2009005978A (es) 2009-06-16
CA2669819A1 (en) 2008-06-12
BRPI0720220B1 (pt) 2020-06-09
HRP20160585T1 (hr) 2016-06-17
EA200970535A1 (ru) 2009-10-30
HUE028769T2 (en) 2017-01-30
AP2479A (en) 2012-09-27
ME02498B (me) 2017-02-20
AP2009004874A0 (en) 2009-06-30
KR20090086604A (ko) 2009-08-13
NO341983B1 (no) 2018-03-05
JO3271B1 (ar) 2018-09-16
EA016733B1 (ru) 2012-07-30
WO2008068267A1 (en) 2008-06-12
SI2099758T1 (sl) 2016-07-29
AU2007328887B2 (en) 2013-01-17
NO20092542L (no) 2009-08-25
PL2099758T3 (pl) 2016-08-31
JP2010511668A (ja) 2010-04-15
KR101490222B1 (ko) 2015-02-05
TWI406659B (zh) 2013-09-01
DK2099758T3 (en) 2016-06-13
IL199083A0 (en) 2010-03-28
PT2099758E (pt) 2016-06-02
JP5466011B2 (ja) 2014-04-09
EP2099758A1 (en) 2009-09-16
UA100972C2 (ru) 2013-02-25
BRPI0720220A2 (pt) 2013-12-24
ES2573689T3 (es) 2016-06-09
RS54794B1 (sr) 2016-10-31
AR064151A1 (es) 2009-03-18
EP2099758B1 (en) 2016-03-09
NZ576823A (en) 2012-01-12
IL199083A (en) 2014-08-31
TW200838528A (en) 2008-10-01
US20100048566A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
CN101553470A (zh) 抗菌的喹啉衍生物
CN101070304B (zh) 喹啉衍生物及其作为分枝杆菌抑制剂的应用
CN101547907A (zh) 抗菌的喹啉衍生物
CN1910154B (zh) 用作分枝杆菌抑制剂的喹啉衍生物
CN101277695A (zh) 作为抗菌剂的喹啉衍生物
CN101232884B (zh) 作为抗菌剂的喹啉衍生物
CN101277696B (zh) 作为抗菌药物的喹啉衍生物
CN101553471A (zh) 抗菌喹啉衍生物
CN101273016B (zh) 抗菌喹啉衍生物
CN101541752A (zh) 抗菌的喹啉衍生物
TWI413520B (zh) 用作抗細菌劑之喹啉衍生物
CN101247811B (zh) 作为抗菌剂的喹啉衍生物
CN104981238B (zh) 抗细菌化合物
CN101277698A (zh) 作为抗菌剂的喹啉衍生物
CN101252928B (zh) 作为抗菌剂的喹啉衍生物
HK1124233B (en) Quinoline derivatives as antibacterical agents
HK1122804B (en) Antibacterial quinoline derivatives
HK1137431B (en) Antibacterial quinoline derivatives
HK1208437B (zh) 抗菌的喹啉衍生物
HK1124234B (en) Quinoline derivatives as antibacterial agents
HK1137441B (en) Antibacterial quinoline derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1137435

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20091007

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1137435

Country of ref document: HK